DE602007011756D1 - Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen - Google Patents

Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen

Info

Publication number
DE602007011756D1
DE602007011756D1 DE602007011756T DE602007011756T DE602007011756D1 DE 602007011756 D1 DE602007011756 D1 DE 602007011756D1 DE 602007011756 T DE602007011756 T DE 602007011756T DE 602007011756 T DE602007011756 T DE 602007011756T DE 602007011756 D1 DE602007011756 D1 DE 602007011756D1
Authority
DE
Germany
Prior art keywords
treatment
kinase
psychiatrical
heather
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011756T
Other languages
English (en)
Inventor
Mauro Corsi
Isidore Faiferman
Pich Emilio Merlo
Emiliangelo Ratti
Paul Bryan Wren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of DE602007011756D1 publication Critical patent/DE602007011756D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
DE602007011756T 2006-06-16 2007-06-13 Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen Active DE602007011756D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612026.5A GB0612026D0 (en) 2006-06-16 2006-06-16 New use
PCT/EP2007/055858 WO2007144390A1 (en) 2006-06-16 2007-06-13 Use of a p38 kinase inhibitor for treating psychiatric disorders

Publications (1)

Publication Number Publication Date
DE602007011756D1 true DE602007011756D1 (de) 2011-02-17

Family

ID=36775828

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007011756T Active DE602007011756D1 (de) 2006-06-16 2007-06-13 Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen

Country Status (13)

Country Link
US (1) US7989479B2 (de)
EP (1) EP2029139B1 (de)
JP (1) JP2010528980A (de)
KR (1) KR20090020703A (de)
CN (1) CN101500567B (de)
AT (1) ATE494008T1 (de)
AU (1) AU2007259224A1 (de)
CA (1) CA2657390A1 (de)
DE (1) DE602007011756D1 (de)
EA (1) EA015483B1 (de)
ES (1) ES2358931T3 (de)
GB (1) GB0612026D0 (de)
WO (1) WO2007144390A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1864975E (pt) * 2002-02-12 2010-12-27 Glaxosmithkline Llc Derivados de nicotinamida úteis como inibidores de p38
CN102633715B (zh) * 2012-03-23 2014-03-26 无锡爱内特营养保健品科技有限公司 一种丝裂原蛋白激酶p38的抑制剂及其制备方法
US9707219B2 (en) * 2013-07-10 2017-07-18 Glaxosmithkline Intellectual Property (No.2) Limited Losmapimod for use in treating glomerular disease
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
WO2019103926A1 (en) * 2017-11-21 2019-05-31 Saint Louis University P38 inhibitors for the treatment of fshd

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373883A1 (en) * 1999-07-02 2001-01-11 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
PT1864975E (pt) 2002-02-12 2010-12-27 Glaxosmithkline Llc Derivados de nicotinamida úteis como inibidores de p38
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
US20050165232A1 (en) * 2002-05-13 2005-07-28 Richard Beresis Phenyl substituted imidaopyridines and phenyl substituted benzimidazoles
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7887802B2 (en) * 2004-07-16 2011-02-15 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
US20080051416A1 (en) 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
GB0512429D0 (en) 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP2032142A4 (de) 2006-06-16 2010-07-21 Glaxo Group Ltd Neuartige verbindungen
EP2031965A4 (de) 2006-06-16 2010-06-30 Glaxo Group Ltd Neuartige verbindungen
US20100144755A1 (en) 2006-06-16 2010-06-10 Glaxo Group Limited Novel Compounds

Also Published As

Publication number Publication date
JP2010528980A (ja) 2010-08-26
AU2007259224A1 (en) 2007-12-21
CN101500567A (zh) 2009-08-05
KR20090020703A (ko) 2009-02-26
EP2029139A1 (de) 2009-03-04
US20100016377A1 (en) 2010-01-21
EP2029139B1 (de) 2011-01-05
WO2007144390A1 (en) 2007-12-21
US7989479B2 (en) 2011-08-02
ES2358931T3 (es) 2011-05-16
EA015483B1 (ru) 2011-08-30
EA200900034A1 (ru) 2009-06-30
ATE494008T1 (de) 2011-01-15
CN101500567B (zh) 2012-05-16
GB0612026D0 (en) 2006-07-26
CA2657390A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
RS95404A (en) Thiazolidinones and the use thereof as polo-like kinase inhibitors
ATE517896T1 (de) P38-kinase-inhibitoren
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
EA200802054A1 (ru) Ингибиторы фермента
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
DE602007011756D1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
WO2006002763A3 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины